Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Fibroin/sulfated alginate membranes containing exosomes of stem cells treated with B and Zn-doped hydroxyapatite for periosteal tissue engineering.

Akbaba S., Turacli Karaguven SO., Evis Z., Tezcaner A.

Laboratory Study on Immune Modulation, published in J Mater Chem B (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Mater Chem B (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41906986
DOI
10.1039/d5tb02784e

Abstract (original English)

Periosteal regeneration requires tissue engineering strategies that simultaneously support osteogenesis, angiogenesis, and immunomodulation. In this study, fibroin/sulfated alginate (F/sA) composite membranes loaded with exosomes derived from human adipose-derived stem cells (hADSCs) treated with pure, 4 mol% B-doped, and 4 mol% B and 8 mol% Zn-doped hydroxyapatite (HA) were developed for periosteal tissue engineering. It was hypothesized that incorporation of sA and HA-conditioned exosomes enhances osteoimmunomodulation while preserving scaffold integrity. F/sA membranes with varying sulfated alginate content (0-20 wt%) were fabricated and characterized. Increasing sulfated alginate content enhanced water uptake and degradation while reducing tensile strength and Young's modulus. A 95 : 5 F/sA ratio was identified as optimal exosome delivery composition, exhibiting the highest hADSC viability and reducing IL1B and CASP1 levels in THP-1 macrophages ( p < 0.05). It was also found that exosomes isolated from pure and doped HA-treated hADSCs showed treatment-dependent alterations in the cargo. The 8 mol% B-doped HA group significantly increased exosome yield, while all HA treatments reduced protein/particle and DNA/particle ratios. Doped HA treatments significantly increased RNA/particle ratio ( p < 0.05). Exosome-loaded F/sA membranes enhanced early cell attachment and proliferat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansTissue EngineeringExosomesAlginatesDurapatiteFibroinsZincStem CellsPeriosteumCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research